



CanaQuest 37- 4120 Ridgeway Drive, Mississauga, Ontario L5L 5S9, Canada www.canaquest.com Tel: 416.704.3040

CanaQuest Medical Corp - Introduction

Mentanine® increases efficacy of Pharma Grade CBD 10x in the Brain for the treatment of mental health ailments.....by interacting with the Central Nervous System "CNS"

CanaQuest (OTC: CANQF) is a Life Science/Pharmaceutical Company developing proprietary Medical Products utilizing cannabinoid molecules and other pharmaceutical grade botanical compounds for the treatment of numerous mental health issues.

Our Vision:

- To be a Global Leader in the formulation and development of health products from cannabis derivatives.

Status:

- Two Commercial Ready Master Formulations, IP Protected, enable us to target identified rare diseases and multiple ailments – initiating Human Clinical Trials.
- Our business model, with an exceptionally low burn rate, positions our company to contract manufacture and sell our formulated products globally, in accordance with regulations - Processing and Distribution Agreement signed.

Proprietary Products:

- **Mentanine®** - Omega-3/CBD Formula. Pre-clinical trials highlighted advantages over every CBD product on the market today, including FDA-approved Epidiolex. (Provisional Patent filed). Pre-clinical trials have shown that Mentanine® has **~10x efficacy** compared to Pharma Grade CBD. As well, Mentanine® is delivered sublingually and bypasses the digestive system and liver.
- **Mentabinol®** - THC isolate/L-Theanine formula, is **the only safer alternative** medication to any THC product on the market, including FDA-approved Sativex. (International Patent filed).

Highlights:

- **Pharma - Regulatory pathways**

CanaQuest's scientifically developed formulation **Mentanine®**, is designed to follow the same regulatory pathway as **GW Pharmaceutical Plc's.**, Epidiolex, CBD-based medication approved by the FDA, generated first year revenue of \$290 Million.

- **Full-service regulatory affairs consulting team**

Experience Regulatory Affairs Consulting Team, comprised of globally recognized experts, including former US-FDA staff. Expertise in rare diseases and other under-served disease areas, and scientists with many successful FDA interactions, orphan drug designations and other expedited program submissions.

- **Drug Identification Number “DIN”**

The Company has initiated the process to obtain approval for a Drug Identification Number “DIN” from US-FDA (seeking Orphan Drug Status – FDA approval expected in less than two years) and is also pursuing approval for a DIN from Health Canada.

- **ADC Biomedical Corp. (e-commerce)**

CanaQuest’s Subsidiary, ADC BioMedical Corp, was awarded a Health Canada licence to sell, import and export cannabis and cannabinoid products for Medical purposes.

www.canaqueststore.com e-commerce site developed to sell products to Canadian-based registered patients.

- **Business of the Year Award**

CanaQuest won the Go Global Awards (2019) "Business of the Year – Category of Life Science," presented by the International Trade Council.

Science:

- **Industry / University Partnerships**

The Company is the industry partner for research and product development with:

- **Dr. Steven Laviolette, B.Sc., Ph.D., Professor and Neuroscientist**, and his 13 member scientific team at **Western University**, London, Ontario, Canada. Dr. Laviolette’s team has been published in the top tier of neuroscience and psychiatry journals in the world, including being featured in the Journal of Neuroscience.
- **Dr. David Ma, Ph.D. Professor**, and his 5 member scientific team at **University of Guelph**, Guelph, Ontario, Canada. Developed R & D Partnership Program (Pets - Dogs, Cats) – leveraging from Western University, Dr. Steven Laviolette’s science and pre-clinical trial results. To date, Dr. Ma has authored over 130 peer reviewed publications.

Management:

- **100+ years of experience**

Our co-founders previously founded and built Cymat Technologies, which was listed on the TSE with a valuation greater than **\$150M** when they resigned. Collectively, CanaQuest’s team has more than 100 years of experience in management, product development, processing, and commercialization. We are currently developing our Scientific and Marketing Advisory Boards.